Neuphoria Therapeutics Inc (NEUP)

$4.84 +0.14 (2.98%)
Market Cap 25.40M
Revenue (ttm) 15.65M
Net Income (ttm) -370,000.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2.36%
Debt to Equity Ratio 0.00
Volume 129,400
Avg Vol 47,234
Day's Range N/A - N/A
Shares Out 5.41M
Stochastic %K 33%
Beta 0.72
Analysts Hold
Price Target $2.30

Company Profile

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 439 5551
Address:
100 Summit Drive, Burlington, United States
skyrockets_Inc
skyrockets_Inc Jun. 3 at 4:31 PM
$NEUP I had to take this free gift and buy some more. Could this be the last dump to shake out more retail before news drops? Support at 100day SMA at 4.57
2 · Reply
BuyNow_SellLater
BuyNow_SellLater Jun. 3 at 3:11 PM
$NEUP 2-3 share movement again today, weird
0 · Reply
BuyNow_SellLater
BuyNow_SellLater Jun. 3 at 3:06 PM
$NEUP 4.80 loading
0 · Reply
skyrockets_Inc
skyrockets_Inc Jun. 2 at 5:21 PM
$NEUP We've seen this movie several times now. Fake dump. Will be back above 5.20 in a few days tops. Doesn't help that EVERYTHING in bio is red today.
0 · Reply
KingZack25
KingZack25 Jun. 2 at 5:16 PM
$NEUP anyone see the time & sales tape today? Basically every trade going through is for 3 shares. 100% manipulation going on
0 · Reply
skyrockets_Inc
skyrockets_Inc Jun. 1 at 6:26 PM
$NEUP CEO is very active on LinkedIn. Always posting about his book and other things weekly. He has been eerily silent for the past 3 weeks, with no posts. I think officially in quiet period and we will be hearing something in the next coming weeks. Crossing fingers this week :)
2 · Reply
Eliertk
Eliertk May. 29 at 12:14 AM
$NEUP are we ready or 👀😤
0 · Reply
I_am_retail_investor
I_am_retail_investor May. 27 at 6:12 PM
$NEUP - I like Skyrockets positivity, but the siper slow news cycle and slumping # STwits watchers is giving me bag-holder vibes. Why is business disposition taking so long!?
1 · Reply
skyrockets_Inc
skyrockets_Inc May. 26 at 8:31 PM
$NEUP Potential future milestone payments of 4.65% of 460M, or 21M (a potential addition of 3.90/share) on an asset that quite honestly I never even heard of or knew they had licensed to Pfizer. Free bonus.
1 · Reply
skyrockets_Inc
skyrockets_Inc May. 26 at 8:22 PM
$NEUP 8-K Just dropped: "Item 8.01 Other Events On May 21, 2026, Neuphoria Therapeutics Inc. (the “Company”) received a revenue distribution payment of AUD $1.416M from its participation in the former Cancer Therapeutics Cooperative Research Centre (CTx CRC) related to the Company’s licensing of the KAT6 program to Pfizer Inc. following the initiation of dosing of the first subject in the first Phase III Clinical Trial in ER+/HER2- metastatic breast cancer. Based on past program contributions, Neuphoria believes it is eligible to receive approximately 4.65% of future milestone payments, if any, from CTXT, of which the total value to all 17 parties (see below) combined is estimated to be USD$460M. As a passive party, the Company is not able to determine whether future milestones will be achieved, whether the Company will receive any future milestone payments, or the size of any such payments, if received.
1 · Reply
Latest News on NEUP
Neuphoria Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

2026-05-15T18:23:29.000Z - 20 days ago

Neuphoria Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

Neuphoria announces ISS recommends shareholders vote ‘FOR’ director nominees

2025-12-08T13:05:17.000Z - 6 months ago

Neuphoria announces ISS recommends shareholders vote ‘FOR’ director nominees

Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees

Dec 8, 2025, 8:00 AM EST - 6 months ago

Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees

Neuphoria Therapeutics price target lowered to $7 from $21 at H.C. Wainwright

2025-12-05T12:45:20.000Z - 6 months ago

Neuphoria Therapeutics price target lowered to $7 from $21 at H.C. Wainwright

Neuphoria Therapeutics responds to Lynx1’s revised indication of interest

2025-12-04T13:10:52.000Z - 6 months ago

Neuphoria Therapeutics responds to Lynx1’s revised indication of interest

Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium

Dec 4, 2025, 8:00 AM EST - 6 months ago

Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium

Neuphoria Therapeutics ‘exposes false narratives’ responding to Lynx1

2025-12-01T13:11:12.000Z - 6 months ago

Neuphoria Therapeutics ‘exposes false narratives’ responding to Lynx1

Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

Dec 1, 2025, 8:00 AM EST - 6 months ago

Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

Neuphoria Therapeutics urges stockholders to vote for company nominees

2025-11-24T13:25:32.000Z - 6 months ago

Neuphoria Therapeutics urges stockholders to vote for company nominees

Neuphoria Therapeutics Inc. Sends Letter to Stockholders

Nov 24, 2025, 8:00 AM EST - 6 months ago

Neuphoria Therapeutics Inc. Sends Letter to Stockholders

Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value

Nov 11, 2025, 7:00 AM EST - 7 months ago

Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value

Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process

Oct 27, 2025, 4:29 PM EDT - 7 months ago

Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process

Biotech Alert: Searches spiking for these stocks today

2025-10-27T15:45:14.000Z - 7 months ago

Biotech Alert: Searches spiking for these stocks today

FUSE SMMT

Biotech Alert: Searches spiking for these stocks today

2025-10-24T16:20:11.000Z - 7 months ago

Biotech Alert: Searches spiking for these stocks today

IBIO

Biotech Alert: Searches spiking for these stocks today

2025-10-23T17:05:21.000Z - 8 months ago

Biotech Alert: Searches spiking for these stocks today

IBIO SMMT

Why Is Neuphoria Therapeutics Stock (NEUP) Down 65% Today?

2025-10-21T13:29:41.000Z - 8 months ago

Why Is Neuphoria Therapeutics Stock (NEUP) Down 65% Today?

Neuphoria Therapeutics downgraded to Neutral from Buy at Lucid Capital

2025-10-21T10:05:11.000Z - 8 months ago

Neuphoria Therapeutics downgraded to Neutral from Buy at Lucid Capital

Neuphoria Therapeutics Inc trading resumes

2025-10-20T21:00:12.000Z - 8 months ago

Neuphoria Therapeutics Inc trading resumes

Neuphoria AFFIRM-1 trial misses primary endpoint, to discontinue SAD program

2025-10-20T20:50:24.000Z - 8 months ago

Neuphoria AFFIRM-1 trial misses primary endpoint, to discontinue SAD program

Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder

Oct 20, 2025, 4:15 PM EDT - 8 months ago

Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder

Neuphoria Therapeutics Inc trading halted, news pending

2025-10-20T20:10:11.000Z - 8 months ago

Neuphoria Therapeutics Inc trading halted, news pending

Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Sep 29, 2025, 4:54 PM EDT - 8 months ago

Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Neuphoria Therapeutics price target raised to $35 from $18 at Maxim

2025-09-11T13:20:10.000Z - 9 months ago

Neuphoria Therapeutics price target raised to $35 from $18 at Maxim

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

Sep 4, 2025, 7:00 AM EDT - 9 months ago

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 4:05 PM EDT - 10 months ago

Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

May 27, 2025, 4:10 PM EDT - 1 year ago

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

Neuphoria Provides First Quarter 2025 Business Updates

May 20, 2025, 4:22 PM EDT - 1 year ago

Neuphoria Provides First Quarter 2025 Business Updates

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

Mar 3, 2025, 7:30 AM EST - 1 year ago

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

Feb 12, 2025, 7:00 AM EST - 1 year ago

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

Dec 23, 2024, 4:49 PM EST - 1 year ago

Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

skyrockets_Inc
skyrockets_Inc Jun. 3 at 4:31 PM
$NEUP I had to take this free gift and buy some more. Could this be the last dump to shake out more retail before news drops? Support at 100day SMA at 4.57
2 · Reply
BuyNow_SellLater
BuyNow_SellLater Jun. 3 at 3:11 PM
$NEUP 2-3 share movement again today, weird
0 · Reply
BuyNow_SellLater
BuyNow_SellLater Jun. 3 at 3:06 PM
$NEUP 4.80 loading
0 · Reply
skyrockets_Inc
skyrockets_Inc Jun. 2 at 5:21 PM
$NEUP We've seen this movie several times now. Fake dump. Will be back above 5.20 in a few days tops. Doesn't help that EVERYTHING in bio is red today.
0 · Reply
KingZack25
KingZack25 Jun. 2 at 5:16 PM
$NEUP anyone see the time & sales tape today? Basically every trade going through is for 3 shares. 100% manipulation going on
0 · Reply
skyrockets_Inc
skyrockets_Inc Jun. 1 at 6:26 PM
$NEUP CEO is very active on LinkedIn. Always posting about his book and other things weekly. He has been eerily silent for the past 3 weeks, with no posts. I think officially in quiet period and we will be hearing something in the next coming weeks. Crossing fingers this week :)
2 · Reply
Eliertk
Eliertk May. 29 at 12:14 AM
$NEUP are we ready or 👀😤
0 · Reply
I_am_retail_investor
I_am_retail_investor May. 27 at 6:12 PM
$NEUP - I like Skyrockets positivity, but the siper slow news cycle and slumping # STwits watchers is giving me bag-holder vibes. Why is business disposition taking so long!?
1 · Reply
skyrockets_Inc
skyrockets_Inc May. 26 at 8:31 PM
$NEUP Potential future milestone payments of 4.65% of 460M, or 21M (a potential addition of 3.90/share) on an asset that quite honestly I never even heard of or knew they had licensed to Pfizer. Free bonus.
1 · Reply
skyrockets_Inc
skyrockets_Inc May. 26 at 8:22 PM
$NEUP 8-K Just dropped: "Item 8.01 Other Events On May 21, 2026, Neuphoria Therapeutics Inc. (the “Company”) received a revenue distribution payment of AUD $1.416M from its participation in the former Cancer Therapeutics Cooperative Research Centre (CTx CRC) related to the Company’s licensing of the KAT6 program to Pfizer Inc. following the initiation of dosing of the first subject in the first Phase III Clinical Trial in ER+/HER2- metastatic breast cancer. Based on past program contributions, Neuphoria believes it is eligible to receive approximately 4.65% of future milestone payments, if any, from CTXT, of which the total value to all 17 parties (see below) combined is estimated to be USD$460M. As a passive party, the Company is not able to determine whether future milestones will be achieved, whether the Company will receive any future milestone payments, or the size of any such payments, if received.
1 · Reply
skyrockets_Inc
skyrockets_Inc May. 26 at 8:06 PM
$NEUP One of the MK-1167 trials is finishing up in two days (5/28/26). Could this be the delay? Waiting for these results to sell MK-1167 outright to Merck. The final P2 trial finishes up in Dec 2026, and Merck will owe NEUP around 30M-40M milestone payment if successful. Makes sense for Merck to buy the drug outright now if it's showing early positive signs.
0 · Reply
isu2b3vrysus
isu2b3vrysus May. 22 at 5:45 PM
$NEUP $NEUP the highest close during the early may fakeout runup was 5.39. If this stock can continue chugging past 5.5 and towards 6 next week, that should be a good indicator of news extremely soon, similar to how RLYB behaved prior to the news. If this dips back down to under 5, we accumulate more and wait again. I think that regardless, this is a very simple play that will reward patience because a good outcome is (no jinx) almost guaranteed, especially with the amount of time that negotiations have drawn on.
1 · Reply
NjordTrade
NjordTrade May. 22 at 3:54 PM
$NEUP good looking
0 · Reply
skyrockets_Inc
skyrockets_Inc May. 22 at 2:29 PM
$NEUP As promised, just bought 10k more shares on this fine Friday. Someone bought 40k premarket which is a great sign. Maybe news Tue after the Holiday??!!!
0 · Reply
isu2b3vrysus
isu2b3vrysus May. 22 at 1:59 PM
$NEUP volume high and ticker price inching up again. is smart money accumulating for the second time?
0 · Reply
skyrockets_Inc
skyrockets_Inc May. 19 at 5:48 PM
$NEUP I can't believe anyone would be selling at this point and at these prices. I'll be buying more on Friday when some funds become available if we're still at these levels....way too cheap imo
1 · Reply
Lima2111
Lima2111 May. 16 at 9:03 AM
$NEUP price down with overall, long overdue market correction but thesis still strong and getting stronger in my opinion. The lastest filings show that register is getting cleaner and more conviction-driven. Quants and market makers like Diadema & Bridgeway leaving, sophisticated event-driven funds arriving, see Balyasny, Vanguard CM and Squadron. The Shay trim of 11% (likely portfolio rebelancing) and HCW neutral are the only yellow flags, if at all and neither breaks the thesis. The Balyasny entry alone more than offsets the Shay reduction in terms of signal quality.​​​​​​​​​​​​​​​​ Plus the fact that they’ve paid off previous debt and done their housekeeping to clean up shell is also a positive signal.
0 · Reply
skyrockets_Inc
skyrockets_Inc May. 15 at 6:06 PM
$NEUP free gift today for anyone with spare change. market is blood red all around .
0 · Reply
Eliertk
Eliertk May. 15 at 5:02 PM
$NEUP 👀
0 · Reply
skyrockets_Inc
skyrockets_Inc May. 15 at 3:31 PM
$NEUP 10Q out. Cash stands at 19.5m at end of Q1. Used some cash to pay off liabilities so stockholder equity is roughly the same as last quarter. Overall good clean financials. Extrapolated to the future, this still puts us at 15m cash + 10m shell or 25m pure liquidation value (no value given to assets), or 4.62/share MINIMUM. Keep in mind that LYNX capital offered to buy the company in December for 4.75/share and the company rejected the offer. LYNX is still holding all shares.
1 · Reply
RDequities
RDequities May. 15 at 12:56 PM
$NEUP s I said the CEO will cash in every month of free money possible and then probably will do something by end of year before his term expires ..This is free money ..I would have done the same
2 · Reply
skyrockets_Inc
skyrockets_Inc May. 14 at 3:23 PM
$NEUP Q/A email from yesterday w/ CEO responses. Sounds like big news within weeks IMO Q: "Hi. Dr. Papapetropoulous, How is the process going? " A: "We are making great progress. Unfortunately, I can't share material details but things are moving along nicely. Warm regards, Spyros" Q: "Thanks! Are you able to share a guess as to whether there will be an update/clarity in 1H 2026? Or is that material? Thanks for the response either way." A: "There will certainly be an announcment related to the progress of the process but unfortunately I cannot provide information on exact timing."
1 · Reply